Hanmi Pharmaceutical Ranks No. 1 in Sustainability Management in Pharmaceutical Industry for Two Consecutive Years


Park Joong-hyun (left), Executive Director of Hanmi Pharm, and Kang Myung-soo, President of Korean Standards Association, at the 2021 Korean Sustainability Conference 2021

Hanmi Pharmaceutical announced that it was ranked No. 1 in sustainability management in the pharmaceutical industry in the Korean Sustainability Index (KSI) Evaluation carried out by the Korean Standards Association (KSA) in 2021 for the second year in a row.

The KSI is a measure of sustainability used by the KSA to evaluate domestic enterprises based on ISO 26000, an international standard for social responsibility. It has been used annually thirteen times since 2009.

Evaluated based on this scheme are 202 enterprises and institutions spread across 48 industries, including pharmaceutical, steel, and trade, where some 25,000 stakeholders, including shareholders, investors, employees, local residents, and suppliers, involved.

Hanmi Pharm recorded a KSI of 51.24 points, the highest in the pharmaceutical industry, the average KSI of which was 48.04, while the average of all industries was 45.87.

Hanmi Pharm recorded high scores in win-win relationships with suppliers and local communities, customer satisfaction, and fair contracts. It was also recognized for the fact that nearly 90% of its sales come from products it has developed itself and that it invests more than 20% of the sales proceeds in new drug R&D.

Source: Yonhap News